Guideline

This document provides general guidance and examples on implementing contact investigations in low- and middle-income settings. The World Health Organization (WHO) policy document "Recommendations for Inves­tigating Contacts of Persons with Infectious Tuberculosis in Low- and Middle-Income Countries", published in late 2012, presents definitions and recommendations for what should be done for contact investigation; this doc­ument presents suggestions and examples of how the recommendations can be put into operation.

This document provides a generic framework for implementing TB diagnostics. Topics covered include managerial, technical, and operational processes required for developing and implementing a national strategy for TB laboratories.

This document presents guidance on the design and implementation of surveys and surveillance systems to measure the burden and trends of drug-resistant tuberculosis.

This document provides practical guidance on translating the World Health Organization's principles and recommendations into a national or local screening strategy.

These guidelines aim to reduce morbidity and mortality related to TB and HIV-associated TB among people who inject drugs (PWID) through the integrated delivery of a comprehensive and holistic package of care. The guidelines provide an update of the 2008 Policy guidelines for collaborative TB and HIV services for injecting and other drug users: an integrated approach.

The purpose of this document is to provide guidance for clinicians, nurses, and hospital infection preventionists on the use of the Xpert MTB/RIF assay when making decisions to discontinue airborne infection isolation for persons with suspected, infectious pulmonary TB.

This hospital discharge approval request form is required in New York City as New York City Health Code mandates health care providers to obtain approval
from the New York City Department of Health & Mental Hygiene (DOHMH) before discharging infectious TB patients from the hospital.

The WHO treatment guidelines for drug-resistant TB contains policy recommendations on priority areas in the treatment of drug-resistant TB.

This document describes the steps necessary to implement the shorter regimen and the new drugs for drug-resistant TB treatment, including diagnosis and bacterial confirmation of drug resistance, treatment regimen design, monitoring of treatment efficacy and safety, and programmatic evaluation.

The goal of this document is to provide practical answers to ethical questions in regard to the End TB Strategy.